Pharmadrug Inc. (G11.F)

0.0050 -0.0055 (-52.38%) As of 08:07AM CEST. Market open.

Pharmadrug Inc.

77 King Street West
Suite 2905
Toronto, ON M5K 1H1
Canada
647-202-1824
https://www.pharmadrug.ca

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Robert J. Steen	CEO & Director	N/A	N/A	N/A
Mr. Kyle Michael Appleby CA, CPA	Chief Financial Officer	N/A	N/A	1975

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Pharmadrug Inc. operates as a specialty pharmaceutical company. It focuses on the research, development, and commercialization of controlled-substances and natural medicines, such as psychedelics, cannabis, and naturally derived approved drugs. The company also engages in the researching and reformulating of established natural medicines; development of synthetic formulations of existing drugs for potential commercialization and distribution; development of cepharanthine, a drug for the treatment of infectious disease and rare cancers; and research and development activities in the psychedelics space for the treatment of non-neuropsychiatric conditions. It has a license agreement with Southwest Research Institute. The company was formerly known as Aura Health Inc. and changed its name to Pharmadrug Inc. in October 2019. Pharmadrug Inc. is based in Toronto, Canada.

Corporate Governance

Pharmadrug Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.